A clinical trial participant becomes incapacitated mid-study and can no longer provide ongoing consent. The investigator should:
-
A
Continue study procedures as originally consented
-
B
Obtain consent from a legally authorized representative and reassess continued participation
-
C
Discontinue all study procedures immediately without LAR consultation
-
D
Consult the IRB before taking any action